PKN3 and pancreatic neoplasm: For example, an siRNA against PKN3 (Atu027) has been in clinical trials as a novel chemotherapeutic agent for solid cancers and pancreatic cancer (in combination with Gemcitabine) [45–47], and exogenous application of the auto-inhibitory PLK peptide from PKN1 has been explored also [48].